U.S.

  • Global
    • BrazilBrazil
    • CanadaCanada
    • GermanyGermany
    • JapanJapan
  • Investors
  • Media Hub
  • Stories
Horizon logo
search
  • Our Company
    • About Us
    • Leadership Team
    • Corporate Social Responsibility
    • Partnering
    • Grant Programs
    • Worldwide Locations
    • Contact Us
  • Our Science
    • Research and Development
    • Pipeline
    • Science Forward
  • Our Medicines
    • Our Portfolio
    • Medical Resources
  • Our Patients
    • Our Commitment
    • Advocacy
      • Overview
      • Resources
    • Disease Information
    • Patient Stories
    • Patient Support
    • Expanded Access
  • Careers
    • Why Horizon
    • Who We Are
    • Benefits
    • Job Opportunities
  • Investors
    • At a Glance
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Governance Overview
      • Whistleblower Hotline
      • Leadership
      • Committee Composition
      • Contact Board
    • Financials & Filings
      • Financial Information
      • SEC Filings
      • GAAP to Non-GAAP Reconciliations
    • Stock Information
      • Stock Quote & Chart
      • Historic Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Annual Reports / Proxy Statements
    • Investors FAQs
    • IR Contact Us
    • IR Email Alerts
  • Media Hub
  • Stories
Follow Us
  • Featured Content
  • Fact Sheets and Downloads
  • Image Library
  • Video Library

Learn
About Us

More

Featured Content

Latest Press Releases

  • Jun 24, 2022 New Analysis Finds UPLIZNA® (inebilizumab) Effective Among European Populations with Neuromyelitis Optica Spectrum Disorder (NMOSD)
  • Jun 15, 2022 Horizon Therapeutics plc Submits Regulatory Filing for UPLIZNA® (inebilizumab) in Brazil
  • Jun 15, 2022 Horizon Therapeutics plc Named One of the Fortune Best Workplaces in Chicago™
See All Press Releases

Statements

Our Commitment to Anti-Racism
Our Commitment to Pay Equity

Named Patient Use Programs

Named Patient Use Program for TEPEZZA® (teprotumumab-trbw)
Named Patient Use Program for UPLIZNA® (inebilizumab-cdon)

Featured Videos

See All Videos

Corporate Brochure

Corporate Brochure

Fact Sheets & Downloads

  • About Horizon Presentation
  • ESG Overview

See All Fact Sheets

Logo Download

Horizon Logo | Full Color
Horizon Logo | Full Color, White Text
Horizon Logo | White
Horizon Logo | Charcoal

If you are looking for additional Horizon media assets, please contact corpcomms@horizontherapeutics.com.

Media Inquiries

For U.S. media inquiries, contact:
Geoff Curtis
Executive Vice President, Corporate Affairs & Chief Communications Officer
media@horizontherapeutics.com
+1 (888) 506-2562

For EU media inquiries, contact:
Ray Gordon
Managing Director
ray@gordonmrm.ie
+353 (87) 2417373

  • Our Company
  • Our Science
  • Our Medicines
  • Our Patients
  • Careers
  • Investors
Follow Us

© 2022 Horizon Therapeutics plc

  • Global Privacy Policy
  • Legal Notice
  • Cookie Policy
  • Contact Us

The information regarding our medicines and the patients they treat on this site is intended only for residents of the U.S.

You are leaving HorizonTherapeutics.com You are leaving HorizonTherapeutics.com. You will be redirected to a website operated by an independent third party. This link is provided solely for your convenience. You are leaving HorizonTherapeutics.com You are about to go to another website that is operated by Horizon. Would you like to continue? You are leaving HorizonTherapeutics.com You will be directed to a product website to learn more about a medicine for Horizon.

Leaving Site

Cancel Continue